$100M facility focused on AI in healthcare planned for Manhattan

A new building is soon to rise in New York City inside which will buzz myriad medical research and clinical activities involving AI.  

The Icahn School of Medicine at Mount Sinai announced plans June 11 to open the Hamilton and Amabel James Center for Artificial Intelligence and Human Health in late 2021 with 40 or so principal investigators plus around 250 graduate students, postdoctoral fellows, computer scientists and support staff.

The center takes its name from a couple who are heavily investing in the project, which will cost around $100 million from various sources to get up and running in Upper Manhattan, Bloomberg is reporting.

According to the school’s announcement, the interdisciplinary center will be the first site in New York to integrate AI, data science and routine genomic screening.

Other key areas of concentration will include AI-aided disease modeling and precision imaging.

“Artificial Intelligence and machine learning are spurring innovation across many different fields but perhaps most significantly in healthcare,” investor Hamilton “Tony” James said in prepared remarks. “I am pleased to support [Mount Sinai’s] mission and accelerate the development of cutting-edge therapies and technologies that have the potential to change lives around the world.”

James is executive vice chairman of the New York-based Blackstone Group.

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

FDA Commissioner Robert Califf, MD, said the clinical community needs to combat health misinformation at a grassroots level. He warned that patients are immersed in a "sea of misinformation without a compass."
 

With generative AI coming into its own, AI regulators must avoid relying too much on principles of risk management—and not enough on those of uncertainty management.

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

Trimed Popup
Trimed Popup